Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 3/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | CCNK | O75909 | 4/20 | 0.45 |
| ▸ | CDK12 | Q9NYV4 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.45 |
| ▸ | CDK2 | P24941 | 3/20 | 0.45 |
| ▸ | CDK7 | P50613 | 3/20 | 0.45 |
| ▸ | CCNH | P51946 | 3/20 | 0.45 |
| ▸ | MNAT1 | P51948 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL268632 | 1.00 | GFER (0.50) | GFERMMP1MMP9MMP13SCN9A | |
| SCHEMBL268593 | 0.90 | TSHR (0.51) | CCNKCDK12GAACCNA2CDK2 | |
| SCHEMBL268594 | 0.90 | TSHR (0.51) | CCNKCDK12GAACCNA2CDK2 | |
| SCHEMBL269121 | 0.86 | POLB (0.48) | GFERCCNKCDK12KMT2A | |
| SCHEMBL269120 | 0.86 | POLB (0.48) | GFERCCNKCDK12KMT2A | |
| SCHEMBL269520 | 0.83 | CCNK (0.47) | GFERCCNKCDK12CCNA2CDK2 | |
| SCHEMBL269519 | 0.83 | CCNK (0.47) | GFERCCNKCDK12CCNA2CDK2 | |
| SCHEMBL271268 | 0.82 | HCRTR2 (0.48) | GFERCCNKCDK12CCNA2CDK2 | |
| SCHEMBL271269 | 0.82 | HCRTR2 (0.48) | GFERCCNKCDK12CCNA2CDK2 | |
| SCHEMBL3821860 | 0.78 | CCNK (0.46) | GFERCCNKCDK12CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133901-B2 | 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-13 | — | — | US | claimed |
| EP-2094685-B1 | 3-HETEROARYL (AMINO OR AMIDO)-1- (BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-19 | — | — | EP | claimed |
| US-20100069418-A1 | 3-HETEROARYL (AMINO OR AMIDO)-1-(BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERIDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-18 | — | — | US | claimed |
| US-8133901-B2 | 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-13 | — | — | US | disclosed |
| EP-2094685-B1 | 3-HETEROARYL (AMINO OR AMIDO)-1- (BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-19 | — | — | EP | disclosed |
| US-20100069418-A1 | 3-HETEROARYL (AMINO OR AMIDO)-1-(BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERIDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069418-A1 | 3-HETEROARYL (AMINO OR AMIDO)-1-(BIPHENYL OR PHENYLTHIAZOLYL) CARBONYLPIPERIDINE DERIVATIVES AS OREXIN RECEPTOR INHIBITORS | HCRTR1, HCRTR2, NPY1R | GFER 1030/4885MMP1 3826/4885MMP9 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.